VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

VERTEX PHARMACEUTICALS INC / MA

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$501.95+2.21 (+0.44%)

Close on Oct 19, 2026

Market cap: $128.10B
P/E (TTM): 29.2
Dividend yield: –

VERTEX PHARMACEUTICALS INC / MA income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2003 2003-12-31
Revenue	12,001	11,020	9,869	8,931	7,574	6,206	4,163	3,048	2,489	1,702	1,032	580	1,212	1,527	1,411	143	102	176	–
Cost of Revenue	1,651	1,531	1,262	1,080	904	736	548	410	275	210	117	40	89	237	64	0	–	–	–
Gross Profit	10,350	9,490	8,607	7,850	6,670	5,469	3,615	2,638	2,214	1,492	915	541	1,123	1,290	1,347	143	–	–	–
Research & Development	3,910	3,630	3,163	2,540	1,938	1,645	1,755	1,416	1,325	1,048	996	856	882	766	708	637	550	517	–
Selling, General & Admin	1,753	1,464	1,137	945	840	771	659	558	496	433	377	305	356	433	401	188	130	101	–
Advertising Expenses	203	86	46	–	–	–	–	44	35	31	25	16	20	59	31	0	–	–	–
Total Costs & Expenses	7,828	11,253	6,037	4,623	4,792	3,349	2,965	2,412	2,365	1,692	1,499	1,273	1,822	1,480	1,297	839	716	638	–
Operating Income	4,173	-233	3,832	4,307	2,782	2,856	1,198	635	123	9.94	-467	-692	-610	47	114	-696	-614	-463	–
Interest Expense	13	31	44	55	–	58	59	72	69	–	–	–	–	17	38	19	13	13	–
Interest & Investment Income	491	598	615	145	4.90	22	64	38	12	–	–	–	–	1.94	1.88	1.96	5.01	16	–
Other Non-Operating Income	-7.70	-86	-23	-165	4.90	297	192	-0.79	-81	4.13	-6.72	30	6.89	0.31	-16	–	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	0	0	-0.18	14	1.26	2.21	51	41	1.84	2.07	1.50	6.24	4.32	92
Asset Impairment Charges	–	–	–	–	–	–	–	–	1.95	0	2.52	1.69	7.59	0	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	0	-1.08	-77	0	0	0	-55	0	0	–	–	0.63	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.39	-0.06	-0.04	-2.21	-0.01	–
Pretax Income	4,643	249	4,380	4,232	2,730	3,117	1,395	600	-16	-67	-558	-735	-626	32	60	-755	-642	-460	–
Income Tax Expense	690	784	760	910	388	405	218	-1,487	-107	17	30	6.96	-122	-0.28	19	0	–	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	-112	-556	-738	-504	32	–	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	0	0	-0.91	-184	-83	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	2,712	1,177	2,087	92	-84	-588	-743	-688	-51	41	-755	-642	-460	–
Minority Interest in Earnings	–	–	–	–	–	0	0	-9.79	-172	28	-32	–	-243	56	12	0	–	–	–
Net Income	3,953	-536	3,620	3,322	2,342	2,712	1,177	2,097	263	-112	-556	-739	-445	-107	30	-755	-642	–	–
Net Income to Common	–	–	–	–	–	2,712	1,177	2,096	263	-112	-556	-738	-504	32	29	-755	-642	–	–
EPS (Basic)(per share)	15.46	-2.08	14.05	12.97	9.09	10.44	4.58	8.24	1.06	-0.46	-2.31	-3.14	-1.98	-0.50	0.14	-3.77	-3.71	-3.27	–
EPS (Diluted)(per share)	15.32	-2.08	13.89	12.82	9.01	10.29	4.51	8.09	1.04	-0.46	-2.31	-3.14	-1.98	-0.50	0.14	-3.77	-3.71	-3.27	–
Shares Outstanding (Basic, Weighted)(shares)	256	258	258	256	258	260	257	254	249	245	241	235	225	212	205	200	173	141	–
Shares Outstanding (Diluted, Weighted)(shares)	258	258	261	259	260	263	261	259	253	245	241	235	225	215	209	200	173	141	–
EBITDA	4,383	-26	4,013	4,456	2,908	2,966	1,304	708	185	71	-405	-629	-562	85	149	-666	-584	-431	–
Net Interest Income	–	–	-44	-55	-62	-58	-59	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 86.0%
Operating margin: 38.0%
Net margin: 35.0%
Return on equity, FY2025: 22.5%

Financial strength

Current ratio: 3.19
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 156.0%

Valuation

P/E ratio: 29.2
Price to sales: 10.18
Price to book: 6.33
Dividend yield: –